The report titled “Global Myasthenia Gravis Market: Size, Trends & Forecasts (2017-2021)” provides a detailed analysis of the myasthenia gravis market with description of market size and growth. The analysis includes market size in terms of value, and market share on the basis of therapy, by cases and by severity.
The report also provides a brief regional analysis of the US. The analysis includes market size in terms of number of patients on the basis of types of myasthenia gravis. Geographically, the Americas were the largest market and is expected to dominate the market in the forecasted period also. The growth in the market is estimated on the back of rising elderly population in the region.
Furthermore, the report also assesses the key opportunities available in the market and outlines the market dynamics that are and will be accountable for growth of the industry. Growth of the global myasthenia gravis market has also been forecasted for the period 2017-2021, taking into consideration previous growth outlines, growth drivers and the existing and forthcoming trends.
Some of the prominent players of the market include Avadel Pharmaceuticals, Hoffmann-La Roche, Pfizer, and Argenx. A brief company profiling of these major players have also been provided in the report on the basis of aspects like business overview, financial overview and business strategies adopted by respective companies.
Myasthenia gravis is a chronic neuromuscular disease that leads to weakness in the skeletal muscles, which help in the breathing and movement of the body parts including the arms and legs. The word ‘myasthenia gravis’ has Latin and Greek origin and means serious muscle weakness. Myasthenia Gravis is rare and only affects 14 to 20 people out of every 100,000. The main symptom of myasthenia gravis is weakness in the voluntary skeletal muscles, which are muscles under one’s control. Weakness associated with MG typically gets worse with more activity and improves with rest.
The disease is categorized into six types namely: Early-Onset MG, Late-Onset MG, Thymoma-Associated MG, MG with Anti-Musk Antibodies, Ocular MG, and MG with no detectable AChR and MuSK Antibodies. Myasthenia gravis is caused by an error in the transmission of nerve impulses to muscles. Major treatments available for MG are Symptomatic Treatment, Rapid Short-Term Immune-Modulating Treatment, Chronic Long-Term Immune-Modulating Treatment and Surgery.
The global myasthenia gravis market has increased over the past few years and projections are made that the market would rise in the forecasted period i.e. 2017 to 2021 at a significant growth rate. The global myasthenia gravis market is expected to boost by the major factors such as rising geriatric population, technological advancements, approval of monoclonal antibodies, strategies such as mergers and acquisitions etc. Yet the market growth is restrain by some challenges such as competition from off-label drugs, limited availability of FDA approved drugs, high cost of the treatment etc.
3.1.1 Global Myasthenia Gravis Drugs Market by Value
3.1.2 Global Myasthenia Gravis Market by Therapy
Anticholinesterase inhibitors
Immunosuppressants
Intravenous Immune Globulins
3.1.3 Global Myasthenia Gravis Market by Cases
Peripheral muscles
Ocular Muscles
Bulbar Muscles
3.1.4 Global Myasthenia Gravis Cases by Severity
Regional Analysis
4.1 The US Myasthenia Gravis Market Analysis
4.1.1 The US Myasthenia Gravis Market by Total Patient Volume
4.1.2 The US Myasthenia Gravis Market by 2nd Line Patient Volume
4.1.3 The US Myasthenia Gravis Market by 3rd Line Severe Chronic Refractory Patient Volume
4.1.4 The US Myasthenia Gravis Market by Crisis Patient Volume
For any enquires before buying, connect with us @ enquiry@orbisresearch.com
About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
